- Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma
-
Cha J, Seong J, Lee IJ, Kim JW, Han KH
- KMID: 1793165
- Yonsei Med J.
- 2013 Sep;54(5):1178-1185.
- doi: 10.3349/ymj.2013.54.5.1178
PURPOSE: Sorafenib is an effective systemic agent for advanced hepatocellular carcinoma. To increase its efficacy, we evaluated the feasibility and benefit of sorafenib combined with radiotherapy. MATERIALS AND METHODS: From July... -
- CITED
-
- Close
- SHARE
-
- Close
- A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
-
Lee KW, Yun T, Song EK, Na II, Shin H, Bang SM, Lee JH, Lee ST, Kim JH, Yoon SS, Lee JS, Park S, Kim BK, Kim NK
- KMID: 1712739
- J Korean Med Sci.
- 2005 Aug;20(4):598-602.
- doi: 10.3346/jkms.2005.20.4.598
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We... -
- CITED
-
- Close
- SHARE
-
- Close
- Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer: Comparative Analysis between 1st-line and 2nd-line Docetaxel
-
Joung JY, Jeong IG, Han KS, Kim TS, Yang SO, Seo HK, Chung J, Cho KS, Lee KH
- KMID: 2158196
- Yonsei Med J.
- 2008 Oct;49(5):775-782.
- doi: 10.3349/ymj.2008.49.5.775
PURPOSE: This study was undertaken to investigate the outcomes associated with docetaxel treatment of Korean patients with hormone-refractory prostate cancer (HRPC) and to compare its clinical efficacies in 1st and... -
- CITED
-
- Close
- SHARE
-
- Close
